On Wednesday, the nuclear startup announced that its isotope test facility had successfully completed the final safety analysis, ending several months of doubt about whether the company could meet the government's schedule for starting up a reactor.
Oklo stated that the Groves facility has progressed from the documentation stage to the Energy Department's last pre-startup evaluation.
After receiving authorization, the site can load nuclear fuel and commence start-up tests to reach first criticality, defined as the moment a reactor maintains a self-sustaining nuclear chain reaction.
Oklo plans to leverage the Groves plant to establish a reliable source of high-value radioisotopes for medical and industrial applications. America has long depended on old foreign facilities for most of its isotope needs.
Get your free investing masterclass bonus when you join Market Briefs, our free daily newsletter
Yet the primary hurdle is still delivering a commercial reactor quickly enough to meet investor expectations. In contrast to Oklo's larger Aurora models, the Groves reactor produces no electricity. Oklo has been readying its first Aurora power plant at Idaho National Laboratory, and is simultaneously building a fuel fabrication facility there.
For the moment, a test reactor represents an initial step.
In addition to developing a domestic isotope supply, Oklo seeks to strengthen the country's nuclear fuel stockpiles. While the United States builds domestic supply chains for advanced nuclear fuel types like HALEU, Oklo is exploring plutonium as a temporary bridging fuel.
Toward that goal, the startup might have already identified a short-term solution for its fuel requirements. In a recent development, Oklo signed a preliminary agreement with Centrus Energy to secure a multi-year HALEU supply, enough to power as many as five Aurora reactors starting in 2029. Until that time, the first Aurora powerhouse is planned to operate using fuel reclaimed from the Experimental Breeder Reactor II, decommissioned in 1994.
Oklo is participating in a Department of Energy program that aims to have at least three test reactors operating at national laboratories by July 4. The Groves reactor, while not generating electricity, serves as a critical stepping stone for the company to demonstrate its technology and secure the necessary licensing for its larger Aurora power plants. The safety clearance removes one of the most significant uncertainties hanging over Oklo's near-term timeline, giving investors more confidence in the company's ability to execute on its ambitious plans for both isotope production and commercial power generation.
This clearance also underscores the broader push by U.S. regulators to accelerate advanced nuclear deployment. By proving that its safety documentation meets federal standards, Oklo demonstrates a viable path from design to operation - a key concern for investors in a sector where licensing delays have historically plagued startups. The company's dual focus on medical isotopes and small modular reactors aligns with government priorities to reduce foreign dependence in both areas.
Subscribe to Market Briefs, our free daily newsletter, and claim your bonus investing masterclass
